12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Xoma preclinical data

In a mouse model of diabetes, XMetA significantly reduced HbA1c and non-HDL-C from baseline to week 6...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >